CMS draft proposal refuses to cover Lilly's Amyvid
This article was originally published in Scrip
Executive Summary
The US Centers for Medicare & Medicaid Services (CMS) has issued a draft decision concluding that positron emission tomography (PET) amyloid-beta (Aβ) imaging "is not reasonable and necessary" under the Social Security Act.